When journalist Jon Gluck learned he had multiple myeloma, doctors told him he had 18 months to live. That was 20 years ago. ...

At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine for patients with advanced ...

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Tango Therapeutics rebounds with a stronger pipeline, renewed focus on PRMT5 inhibitors, and key data ahead despite past ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

From 2020 to 2024, universities contributed patents underpinning 50% of FDA-approved drugs. 87% of those academic ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Around the world, Global Capability Centres are no longer just doing the work—they’re shaping it. At the final Bosch ...